“…The other intercalating agent studied, doxorubicin, also shows higher activity against exponential than against plateau-phase cultures (Figure 4b), as has been demonstrated with EMT6 (Twentyman & Bleehen, 1975;Kwok & Twentyman, 1985), CHO (Barranco & Novak, 1974), L1210 (Bhuyan et al, 1977) and LoVo (Drewinko et al, 1981) cells. Such cycle selectivity of intercalating drugs appears to reflect the activity of topoisomerase II, which declines in noncycling cells (Sullivan et al, 1986).…”